Eli Lilly and Co (LLY) Stock AnalysisLLYStock AnalysisEli Lilly and Co

Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Eli Lilly is a good buy right now due to its recent FDA approval for Mounjaro, which is expected to significantly boost sales, as evidenced by a 45% revenue increase to $4.8 billion last quarter. Additionally, the stock's current price of $1,174.61 is well below the average analyst price target of $1,400, suggesting substantial upside potential. However, the stock's RSI of 33.243 indicates it is currently oversold, which could present a buying opportunity, although the recent 5-day change of -6.44% highlights some short-term volatility that investors should be aware of.

22 analysts cover LLY: 13 rate it Buy, 8 Hold and 1 Sell. The average price target is 1,192.